Cargando…

Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1–Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression

Pasireotide, a somatostatin analog, is reported to have anti-proliferative effects in neuroendocrine tumors (NETs). We therefore assessed the efficacy of pasireotide for treating pancreatic and pituitary NETs that develop in a mouse model of multiple endocrine neoplasia type 1 (MEN1). Men1(+/−) mice...

Descripción completa

Detalles Bibliográficos
Autores principales: Walls, Gerard V., Stevenson, Mark, Soukup, Benjamin S., Lines, Kate E., Grossman, Ashley B., Schmid, Herbert A., Thakker, Rajesh V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870877/
https://www.ncbi.nlm.nih.gov/pubmed/26990064
http://dx.doi.org/10.1210/en.2015-1965
_version_ 1782432512380764160
author Walls, Gerard V.
Stevenson, Mark
Soukup, Benjamin S.
Lines, Kate E.
Grossman, Ashley B.
Schmid, Herbert A.
Thakker, Rajesh V.
author_facet Walls, Gerard V.
Stevenson, Mark
Soukup, Benjamin S.
Lines, Kate E.
Grossman, Ashley B.
Schmid, Herbert A.
Thakker, Rajesh V.
author_sort Walls, Gerard V.
collection PubMed
description Pasireotide, a somatostatin analog, is reported to have anti-proliferative effects in neuroendocrine tumors (NETs). We therefore assessed the efficacy of pasireotide for treating pancreatic and pituitary NETs that develop in a mouse model of multiple endocrine neoplasia type 1 (MEN1). Men1(+/−) mice were treated from age 12 mo with 40 mg/kg pasireotide long-acting release formulation, or PBS, intramuscularly monthly for 9 mo. The Men1(+/−) mice had magnetic resonance imaging at 12 and 21 mo, and from 20 mo oral 5-bromo-2-deoxyuridine for 1 mo, to assess tumor development and proliferation, respectively. NETs were collected at age 21 mo, and proliferation and apoptosis assessed by immunohistochemistry and TUNEL assays, respectively. Pasireotide-treated Men1(+/−) mice had increased survival (pasireotide, 80.9% vs PBS, 65.2%; P < .05), with fewer mice developing pancreatic NETs (pasireotide, 86.9% vs PBS, 96.9%; P < .05) and smaller increases in pituitary NET volumes (pre-treated vs post-treated, 0.803 ± 0.058 mm(3) vs 2.872 ± 0.728 mm(3) [pasireotide] compared with 0.844 ± 0.066 mm(3) vs 8.847 ±1.948 mm(3) [PBS]; P < .01). In addition, pasireotide-treated mice had fewer pancreatic NETs compared with PBS-treated mice (2.36 ± 0.25 vs 3.72 ± 0.32, respectively; P < .001), with decreased proliferation in pancreatic NETs (pasireotide, 0.35 ± 0.03% vs PBS, 0.78 ± 0.08%; P < .0001) and pituitary NETs (pasireotide, 0.73 ±0.07% vs PBS, 1.81 ± 0.15%; P < .0001), but increased apoptosis in pancreatic NETs (pasireotide, 0.42 ± 0.05% vs PBS, 0.19 ± 0.03%; P < .001) and pituitary NETs (pasireotide, 14.75 ± 1.58% vs PBS, 2.35 ± 0.44%; P < .001). Thus, pasireotide increased survival and inhibited pancreatic and pituitary NET growth, thereby indicating its potential as an anti-proliferative and pro-apoptotic therapy.
format Online
Article
Text
id pubmed-4870877
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Endocrine Society
record_format MEDLINE/PubMed
spelling pubmed-48708772016-05-25 Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1–Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression Walls, Gerard V. Stevenson, Mark Soukup, Benjamin S. Lines, Kate E. Grossman, Ashley B. Schmid, Herbert A. Thakker, Rajesh V. Endocrinology Original Research Pasireotide, a somatostatin analog, is reported to have anti-proliferative effects in neuroendocrine tumors (NETs). We therefore assessed the efficacy of pasireotide for treating pancreatic and pituitary NETs that develop in a mouse model of multiple endocrine neoplasia type 1 (MEN1). Men1(+/−) mice were treated from age 12 mo with 40 mg/kg pasireotide long-acting release formulation, or PBS, intramuscularly monthly for 9 mo. The Men1(+/−) mice had magnetic resonance imaging at 12 and 21 mo, and from 20 mo oral 5-bromo-2-deoxyuridine for 1 mo, to assess tumor development and proliferation, respectively. NETs were collected at age 21 mo, and proliferation and apoptosis assessed by immunohistochemistry and TUNEL assays, respectively. Pasireotide-treated Men1(+/−) mice had increased survival (pasireotide, 80.9% vs PBS, 65.2%; P < .05), with fewer mice developing pancreatic NETs (pasireotide, 86.9% vs PBS, 96.9%; P < .05) and smaller increases in pituitary NET volumes (pre-treated vs post-treated, 0.803 ± 0.058 mm(3) vs 2.872 ± 0.728 mm(3) [pasireotide] compared with 0.844 ± 0.066 mm(3) vs 8.847 ±1.948 mm(3) [PBS]; P < .01). In addition, pasireotide-treated mice had fewer pancreatic NETs compared with PBS-treated mice (2.36 ± 0.25 vs 3.72 ± 0.32, respectively; P < .001), with decreased proliferation in pancreatic NETs (pasireotide, 0.35 ± 0.03% vs PBS, 0.78 ± 0.08%; P < .0001) and pituitary NETs (pasireotide, 0.73 ±0.07% vs PBS, 1.81 ± 0.15%; P < .0001), but increased apoptosis in pancreatic NETs (pasireotide, 0.42 ± 0.05% vs PBS, 0.19 ± 0.03%; P < .001) and pituitary NETs (pasireotide, 14.75 ± 1.58% vs PBS, 2.35 ± 0.44%; P < .001). Thus, pasireotide increased survival and inhibited pancreatic and pituitary NET growth, thereby indicating its potential as an anti-proliferative and pro-apoptotic therapy. Endocrine Society 2016-05 2016-03-18 /pmc/articles/PMC4870877/ /pubmed/26990064 http://dx.doi.org/10.1210/en.2015-1965 Text en https://creativecommons.org/licenses/by/4.0/ This article has been published under the terms of the Creative Commons Attribution License (CC-BY; https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Copyright for this article is retained by the author(s).
spellingShingle Original Research
Walls, Gerard V.
Stevenson, Mark
Soukup, Benjamin S.
Lines, Kate E.
Grossman, Ashley B.
Schmid, Herbert A.
Thakker, Rajesh V.
Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1–Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression
title Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1–Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression
title_full Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1–Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression
title_fullStr Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1–Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression
title_full_unstemmed Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1–Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression
title_short Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1–Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression
title_sort pasireotide therapy of multiple endocrine neoplasia type 1–associated neuroendocrine tumors in female mice deleted for an men1 allele improves survival and reduces tumor progression
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870877/
https://www.ncbi.nlm.nih.gov/pubmed/26990064
http://dx.doi.org/10.1210/en.2015-1965
work_keys_str_mv AT wallsgerardv pasireotidetherapyofmultipleendocrineneoplasiatype1associatedneuroendocrinetumorsinfemalemicedeletedforanmen1alleleimprovessurvivalandreducestumorprogression
AT stevensonmark pasireotidetherapyofmultipleendocrineneoplasiatype1associatedneuroendocrinetumorsinfemalemicedeletedforanmen1alleleimprovessurvivalandreducestumorprogression
AT soukupbenjamins pasireotidetherapyofmultipleendocrineneoplasiatype1associatedneuroendocrinetumorsinfemalemicedeletedforanmen1alleleimprovessurvivalandreducestumorprogression
AT lineskatee pasireotidetherapyofmultipleendocrineneoplasiatype1associatedneuroendocrinetumorsinfemalemicedeletedforanmen1alleleimprovessurvivalandreducestumorprogression
AT grossmanashleyb pasireotidetherapyofmultipleendocrineneoplasiatype1associatedneuroendocrinetumorsinfemalemicedeletedforanmen1alleleimprovessurvivalandreducestumorprogression
AT schmidherberta pasireotidetherapyofmultipleendocrineneoplasiatype1associatedneuroendocrinetumorsinfemalemicedeletedforanmen1alleleimprovessurvivalandreducestumorprogression
AT thakkerrajeshv pasireotidetherapyofmultipleendocrineneoplasiatype1associatedneuroendocrinetumorsinfemalemicedeletedforanmen1alleleimprovessurvivalandreducestumorprogression